TORONTO, Aug. 14, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States market for biopsy devices will see moderate growth through 2021, driven in part by the aging and increasingly obese population. These demographic groups are at an increased risk of developing diseases such as cancer, and they will therefore drive demand for biopsies when anomalies are detected. In addition, increased public awareness regarding diseases and screening guidelines has led to higher biopsy volumes for patients outside of the aforementioned patient pool.
Innovations in imaging technology have greatly improved image quality and detail, especially for the gastrointestinal (GI) tract and bronchial structures. As visualization equipment provides physicians with higher resolution and more magnified images of the human body, biopsies will become more targeted and precise. As a result, physicians will become increasingly confident in the ability of these systems to accurately locate areas requiring examination, thereby supporting procedure volume expansion.
"Most segments of the US biopsy device market are also seeing a shift toward disposable biopsy devices," said MRG Analyst Jason Lau. "Disposable units offer greater convenience to physicians because they do not require sterilization after each use. Greater adoption of disposable devices will mean that there will be a larger volume of units sold, leading to greater market growth. However, this trend will be less prevalent in private practice or high-volume facilities, where cost-conscious physicians and central sterilization departments continue to make reusable devices, especially forceps, a cost-effective option."
The gynecological biopsy device market will be somewhat negatively affected in the near future by the human papillomavirus (HPV) vaccine, which first became available for adolescents in June 2006. According to the Centers for Disease Control and Prevention, HPV is the cause for nearly all incidents of cervical cancer, which generally develops in women over the age of 30. Although not mandatory, many adolescents have received the vaccine in order to decrease future risk of cervical cancer. Therefore, it is expected that as the current generation of adolescents approaches the at-risk age, the effects of the vaccination will result in a decline in cervical cancers, thus necessitating fewer cervical biopsies.
Millennium Research Group's US Markets for Biopsy Devices 2013 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for breast biopsy devices, GI biopsy devices, soft tissue biopsy needles, bronchial biopsy devices and gynecological biopsy devices in the United States.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
|SOURCE Millennium Research Group|
Copyright©2012 PR Newswire.
All rights reserved